LONDON--(BUSINESS WIRE)--Governments across the world are taking initiatives to increase awareness and provide funding for the development of new drugs for the treatment of sexually transmitted diseases. Such initiatives will encourage vendors to develop strong drugs for the treatment of STDs. Furthermore, this industry research report also presents a competitive analysis of the market by type (viral infections, bacterial infections, and other infections) and geography (Asia, Europe, North America, and ROW).
Competitive vendor landscape
The global sexually transmitted diseases (STD) treatment market is highly competitive with major vendors such as Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., and Merck & Co., Inc, competing based on price, quality, and market presence.
“The STD treatment market has witnessed rapid advances in diagnostic technology. The rapid point-of-care is replacing traditional laboratory testing as POC testing can overcome some of the barriers faced by patients and providers. Furthermore, the market is also witnessing significant advancements in molecular diagnostics. Such advances are expected to ease STD treatment, thereby fueling the growth of the market during the forecast period,” says a senior analyst at Technavio.
Top five STD treatment market vendors
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines for the treatment of serious diseases. The company’s key offerings in the STD treatment market include REYATAZ, SUSTIVA, and BARACLUDE.
Gilead Sciences, Inc.
Gilead Sciences, Inc. is focused on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. The company offers various medicines for the treatment of STDs, which include BIKTARVY, GENVOYA, DESCOVY, ATRIPLA, ODEFSEY, STRIBILD, Truvada, VIREAD, and SYMTUZA.
GlaxoSmithKline plc
GlaxoSmithKline plc owns and operates businesses in various segments, including pharmaceuticals, vaccines, and consumer healthcare. The company’s key offerings in the STD treatment include Tivicay, Triumeq, JULUCA, Epzicom/Kivexa, SELZENTRY, CERVARIX, Fendrix, and PEDIARIX.
Johnson & Johnson Services, Inc.
Johnson & Johnson Services, Inc. is one of the most popular global companies which has business operations in pharmaceutical, medical devices, and consumer segments. The company offers various products for the treatment of STD, including SYMTUZA, Edurant, INTELENCE , PREZISTA, and Rezolsta.
Merck & Co., Inc.
Merck & Co., Inc. owns and operates businesses in various segments, including animal health, pharmaceutical, healthcare services, and alliances. Some of the key offerings of the company in the STD treatment market include RECOMBIVAX HB, GARDASIL, and ISENTRESS.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Female Sexual Dysfunction Treatment Market 2019-2023 - The market research study identifies AMAG Pharmaceuticals Inc., Duchesnay Inc., Emotional Brain BV, Novo Nordisk AS, and Sprout Pharmaceuticals Inc., as the leading players in the global female sexual dysfunction treatment market.
- Global Sex Toys Market 2019-2023 - The market research study identifies Church & Dwight Co., Inc., Doc Johnson Enterprises, LELO, LUVU BRANDS, and Reckitt Benckiser Group plc., as the leading players in the global sex toys market.
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
